Latest Quarterly Report
Filed: 2026-05-13
Key Insights
- Company maintained active capital raising activities through September 2025 ATM program and December 2025 underwritten public offering, indicating ongoing need for working capital to fund operations and development.
- Significant leasehold improvements and construction in progress noted on balance sheet at March 31, 2026, suggesting expansion of manufacturing or research facilities to support product commercialization efforts.
- Investment portfolio includes diversified fixed income securities (US Treasuries, corporate bonds, government agency debt) and money market funds, demonstrating prudent cash management for a pre-revenue or early-revenue biotech company.
- Material relationship with Nippon Shinyaku Co. Ltd. documented as investor and through commercialization/distribution agreements, indicating strategic partnership for market access and potential revenue generation.